Characteristics of prior authorization policies for new drugs in Medicare Part D

Naci, Huseyin, Forrest, Robin, Zhai, Mike, Stofesky, Amanda R. and Kesselheim, Aaron S. (2023) Characteristics of prior authorization policies for new drugs in Medicare Part D. JAMA Health Forum, 4 (2). ISSN 2689-0186

Text (Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D) - Published Version Available under License Creative Commons Attribution. Download (413kB)

• Scopus publication
• Author

Abstract

Health insurance providers in the US can employ prior authorization (PA), for which approval from the insurer is needed before a prescription can be dispensed. Prior authorization is most prevalent among expensive or complex therapies to ensure appropriate use. Physicians report that PA can be administratively burdensome.1,2 In Medicare Part D, drug benefits are administered by a multitude of private plans, each with its own formulary and benefit design. An earlier study found that most new drugs covered in Part D are subject to PA requirements, primarily due to high launch prices.3 However, characteristics of such requirements have not been examined. We sought to describe the characteristics of PA policies for new drugs in Part D to understand whether they are consistent with US Food and Drug Administration (FDA) indications.

Item Type:	Article
Official URL:	https://jamanetwork.com/journals/jama-health-forum
Additional Information:	© 2023 The Authors
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	15 Mar 2023 00:20
Last Modified:	22 Apr 2024 21:33
URI:	http://eprints.lse.ac.uk/id/eprint/118422

Actions (login required)

View Item